JP2016204396A5 - - Google Patents

Download PDF

Info

Publication number
JP2016204396A5
JP2016204396A5 JP2016179732A JP2016179732A JP2016204396A5 JP 2016204396 A5 JP2016204396 A5 JP 2016204396A5 JP 2016179732 A JP2016179732 A JP 2016179732A JP 2016179732 A JP2016179732 A JP 2016179732A JP 2016204396 A5 JP2016204396 A5 JP 2016204396A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
units
collagenase
src
purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016179732A
Other languages
English (en)
Japanese (ja)
Other versions
JP6498167B2 (ja
JP2016204396A (ja
Filing date
Publication date
Priority claimed from US11/703,269 external-priority patent/US20070224184A1/en
Application filed filed Critical
Publication of JP2016204396A publication Critical patent/JP2016204396A/ja
Publication of JP2016204396A5 publication Critical patent/JP2016204396A5/ja
Application granted granted Critical
Publication of JP6498167B2 publication Critical patent/JP6498167B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016179732A 2006-02-22 2016-09-14 セルライト処置用コラゲナーゼ Active JP6498167B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77569006P 2006-02-22 2006-02-22
US60/775,690 2006-02-22
US11/703,269 US20070224184A1 (en) 2006-02-22 2007-02-07 Method for treating cellulite
US11/703,269 2007-02-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015095704A Division JP2015134840A (ja) 2006-02-22 2015-05-08 セルライト処置用コラゲナーゼ

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018182242A Division JP6649449B2 (ja) 2006-02-22 2018-09-27 セルライト処置用コラゲナーゼ

Publications (3)

Publication Number Publication Date
JP2016204396A JP2016204396A (ja) 2016-12-08
JP2016204396A5 true JP2016204396A5 (enExample) 2017-03-30
JP6498167B2 JP6498167B2 (ja) 2019-04-10

Family

ID=38325147

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2008556445A Active JP5775658B2 (ja) 2006-02-22 2007-02-22 セルライト処置用コラゲナーゼ
JP2015095704A Pending JP2015134840A (ja) 2006-02-22 2015-05-08 セルライト処置用コラゲナーゼ
JP2016179732A Active JP6498167B2 (ja) 2006-02-22 2016-09-14 セルライト処置用コラゲナーゼ
JP2018182242A Active JP6649449B2 (ja) 2006-02-22 2018-09-27 セルライト処置用コラゲナーゼ
JP2019200656A Active JP6853331B2 (ja) 2006-02-22 2019-11-05 セルライト処置用コラゲナーゼ

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2008556445A Active JP5775658B2 (ja) 2006-02-22 2007-02-22 セルライト処置用コラゲナーゼ
JP2015095704A Pending JP2015134840A (ja) 2006-02-22 2015-05-08 セルライト処置用コラゲナーゼ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018182242A Active JP6649449B2 (ja) 2006-02-22 2018-09-27 セルライト処置用コラゲナーゼ
JP2019200656A Active JP6853331B2 (ja) 2006-02-22 2019-11-05 セルライト処置用コラゲナーゼ

Country Status (19)

Country Link
US (4) US20070224184A1 (enExample)
EP (1) EP1991258B1 (enExample)
JP (5) JP5775658B2 (enExample)
KR (2) KR20120006063A (enExample)
AU (1) AU2007221225B2 (enExample)
BR (1) BRPI0708186A2 (enExample)
CA (1) CA2643171C (enExample)
DK (1) DK1991258T3 (enExample)
ES (1) ES2553184T3 (enExample)
HR (1) HRP20151182T1 (enExample)
HU (1) HUE025918T2 (enExample)
IL (1) IL193639A (enExample)
MX (1) MX2008010767A (enExample)
NZ (1) NZ570642A (enExample)
PL (1) PL1991258T3 (enExample)
PT (1) PT1991258E (enExample)
RS (1) RS54372B1 (enExample)
SI (1) SI1991258T1 (enExample)
WO (1) WO2007100675A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
CA2593038C (en) * 2005-01-21 2015-03-17 Advance Biofactures Corporation Methods for treating adhesive capsulitis
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
WO2008008468A2 (en) * 2006-07-14 2008-01-17 Duncan Diane I Compositions and methods for fat reduction
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US20110229451A2 (en) * 2009-03-06 2011-09-22 Halozyme, Inc. Temperature sensitive mutants of matrix metalloproteases and uses thereof
JP5284239B2 (ja) * 2009-10-07 2013-09-11 株式会社メタコ スクリーン装置
FR2966734B1 (fr) 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
AU2012325941A1 (en) * 2011-10-21 2014-05-15 Auxilium International Holdings, Inc. Method of treating or reducing EFP
EP4276180B1 (en) 2012-01-12 2026-04-22 Endo Biologics Limited Clostridium histolyticum enzyme
WO2014066622A2 (en) 2012-10-24 2014-05-01 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
US20150196625A9 (en) 2013-01-07 2015-07-16 Rudolph D. Paladini Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
US9744138B2 (en) 2013-03-15 2017-08-29 Biospecifics Technologies Corp. Treatment method and product for uterine fibroids using purified collagenase
US10117892B2 (en) 2013-08-29 2018-11-06 Allergan, Inc. Devices and methods for reducing the appearance of cellulite
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
IL327169A (en) 2017-03-01 2026-05-01 Endo Ventures Ltd A method for assessing and treating cellulite
US11473074B2 (en) 2017-03-28 2022-10-18 Endo Global Aesthetics Limited Method of producing collagenase
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020058755A1 (en) * 2018-09-18 2020-03-26 Endo Global Aesthetics Limited Compositions and methods for treating cellulite
CN113382714A (zh) 2019-01-06 2021-09-10 恩多全球美学有限公司 胶原酶制剂及其制备方法
CA3157517A1 (en) 2019-10-15 2021-04-22 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
WO2021108751A1 (en) * 2019-11-26 2021-06-03 Standard Of Care Corporation Hyaluronidase compositions and methods of using same to treat cellulite
CA3252851A1 (en) * 2022-05-10 2023-11-16 Endo Global Aesthetics Limited Collagenase-mediated methods for reducing bruising in a subject with cellulite

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338300A (en) * 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5332503A (en) * 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
JP3028852B2 (ja) * 1994-06-24 2000-04-04 ロシュ ダイアグノスティックス コーポレーション ヒストリチクス菌から得られるコラゲナーゼおよび2つの他のプロテアーゼの精製混合物
US5589171A (en) * 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
US6958150B2 (en) * 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US5830741A (en) * 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US6086872A (en) * 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
CA2317066A1 (en) * 1997-10-03 1999-04-15 Lavipharm Laboratories, Inc. A prolamine-plant polar lipid composition, its method of preparation and applications thereof
US6022539A (en) * 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
AU6918700A (en) * 1999-08-20 2001-03-19 Howard Murad Pharmaceutical compositions and methods for reducing the appearance of cellulite
CA2593038C (en) * 2005-01-21 2015-03-17 Advance Biofactures Corporation Methods for treating adhesive capsulitis
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
US20210169844A1 (en) * 2019-12-10 2021-06-10 Tulex Pharmaceuticals Inc. Compositions and methods for treating epilepsy, seizures and other conditions

Similar Documents

Publication Publication Date Title
JP2018199733A5 (enExample)
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
Marchetti et al. Efficacy and safety of oral ketamine for the relief of intractable chronic pain: a retrospective 5‐year study of 51 patients
JP2015187125A5 (enExample)
JP2022088517A (ja) 前立腺癌を治療するための組成物
HRP20151182T1 (hr) Kolagenaza za tretiranje celulita
EP2292235A3 (de) Methotrexat-Lösungen
JP2023120246A5 (enExample)
JP2018507243A5 (enExample)
JP2019196370A5 (enExample)
Soyka Transition from full mu opioid agonists to buprenorphine in opioid dependent patients—a critical review
IL309340A (en) Dosing regimen for missing doses of paliperidone long-acting injectable esters
Guslandi et al. Rifaximin for active ulcerative colitis
Zhou et al. Clinical observation on the treatment of oral lichen planus with total glucosides of paeony capsule combined with corticosteroids
Librodo et al. Chronotherapeutic drug delivery
Li et al. Efficacy of bilateral catheter superficial parasternal intercostal plane blocks using programmed intermittent bolus for opioid-sparing postoperative analgesia in cardiac surgery with sternotomy: A randomized, double-blind, placebo-controlled trial
JP2022549621A5 (enExample)
Veloso et al. Topical fixed-dose combinations: a way of progress for pain management?
JP2016505050A5 (enExample)
JP2017524721A5 (enExample)
Ng et al. New drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis
JP2009539916A5 (enExample)
AU2019385373A1 (en) Application of chidamide in combination with R-CHOP, and drug combination
JP2019535830A5 (enExample)
de Kam PhD et al. Single IV sugammadex doses up to 32 mg/kg are not associated with QT/QTc prolongation